Study Completed

Diabetes Mellitus

Bayer Identifier:

15316

ClinicalTrials.gov Identifier:

NCT01248481

EudraCT Number:

Not Available

EU CT Number:

Not Available

GlucoFriend-evaluation the effectiveness of Glucobay when combined with a basal insulin

Trial purpose

To evaluate the effectiveness of Glucobay when combined with a basal insulin under daily-life treatment conditions in a large sample of Korean patients.

Key Participants Requirements

Sex

Both

Age

18 - N/A

Inclusion Criteria
- Signed written informed consent
- Age ≥ 18 years
- Diagnosed of type 2 diabetes for at least 6 months prior to enrollment
- Patients treated with stable dose of a basal insulin (insulin glargine or insulin detemir) at least 2 months
- HbA1C≥7.5 and ≤10.0%
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information

Trial summary

Enrollment Goal

539

Trial Dates

September 2010 - July 2012

Phase

N/A

Could I Receive a placebo

Products

Acarbose (Precose/Glucobay, BAYG5421)

Accepts Healthy Volunteer

Where to participate

Status	Institution	Location
Completed		Many Locations, Korea, Republic Of

Primary Outcome

Change in HbA1c
Time Frame:
After 20 weeks
Safety Issue:
No

Secondary Outcome

Duration and dose of acarbose treatment
Time Frame:
After 20 weeks
Safety Issue:
No
Postprandial Blood Glucose
Time Frame:
After 20 weeks
Safety Issue:
No

Trial design

Combined use of a basal insulin and Glucobay For reducing PPG to end diabetes progress

Trial Type

Observational

Intervention Type

Drug

Trial Purpose

N/A

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.